<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="respectively, a &amp;gt;10-fold increase in activity relative to the FDA-approved" exact="teriflunomide" post="(IC50 = 307.1 nmol/L). The X-ray crystal structure of"/>
 <result pre="10 505.88. It is much more potent than that of" exact="teriflunomide" post="or brequinar and is also by far the most"/>
 <result pre="animal models. In addition, the combination administration of S312 and" exact="oseltamivir" post="resulted in 100% protection of the infected mice, superior"/>
 <result pre="with an oseltamivir-resistant virus and had a remarkable advantage over" exact="oseltamivir" post="to treat the late phase of the infectious disease."/>
 <result pre="the DHODH inhibitor with DAA to overcome drug resistance. As" exact="leflunomide" post="and teriflunomide are used to treat autoimmune diseases such"/>
 <result pre="inhibitor with DAA to overcome drug resistance. As leflunomide and" exact="teriflunomide" post="are used to treat autoimmune diseases such as rheumatoid"/>
 <result pre="efficacy too. As anticipated, the combination use of S312 and" exact="oseltamivir" post="significantly reduced the levels of IL-6, MCP-1, IL-5, KC/GRO"/>
 <result pre="concept for the treatment of COVID-19, the clinical trial of" exact="leflunomide" post="has been initiated in England and founded by LifeArc"/>
 <result pre="ReisRAGCalilFAFelicianoPRPinheiroMPNonatoMCThe dihydroorotate dehydrogenases: past and presentArch Biochem Biophys201763217519110.1016/j.abb.2017.06.01928666740 WangMCaoRZhangLYangXLiuJXuMShiZHuZZhongWXiaoGRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
</results>
